NCT06483555 2026-04-01
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT05733689 2026-03-10
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Phase 1 Recruiting
NCT07193862 2026-02-27
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
Phase EARLY_PHASE1 Recruiting
NCT06384560 2026-02-13
PREOPANC-5
Amsterdam UMC, location VUmc
Phase 1/2 Recruiting
NCT03484299 2025-10-29
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
Phase 1 Recruiting
NCT05132504 2025-07-18
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
Phase 2 Recruiting
NCT04084496 2025-05-30
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Sun Yat-sen University
Phase 2 Recruiting
NCT06714604 2024-12-03
ADVANTAGE
Sahlgrenska University Hospital
Phase 3 Recruiting
NCT05529940 2024-11-27
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
Seoul National University Hospital
Phase 3 Recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT06068023 2023-10-05
ADAPTA
Fondazione Poliambulanza Istituto Ospedaliero
Recruiting
NCT03825861 2020-11-10
FOLFIRINOX
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting